IKT Inhibikase Therapeutics, Inc.
$2.34▲ +0.43%
Healthcare
Other
After hours
$2.34▲ +0.00%
Sep 11, 7:30 PM ET
Volume 303.2K
Avg Volume (10D) 352.0K
Key Metrics & Fundamentals
Market Cap
$326.51M
P/E Ratio
–
Div Yield
–%
52W Range
1.33 - 2.61
% vs 50 MA
1.63%
% vs 200 MA
23.67%
RSI-14
46.6
MACD Histogram
-0.0200
Beta (1Y vs SPY)
1.45
Free Cash Flow
-$12.44M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$21.05M
COGS
–
Operating Exp
$21.05M
Operating Income
-$21.05M
EBIT
-$21.05M
Pretax Income
-$19.59M
Net Income
-$19.59M
EPS (Diluted)
-0.11
Price & Volume History
Loading chart…
Recent News
Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity
GlobeNewswire · Aug 11, 2026 8:01 PM
Inhibikase Therapeutics Wins US FDA Orphan Drug Status for IKT-001 in Pulmonary Arterial Hypertension
MT Newswires · Jul 23, 2026 12:43 PM
Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
GlobeNewswire · Jul 23, 2026 12:00 PM
Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility
GlobeNewswire · Jul 14, 2026 12:00 PM
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Jul 2, 2026 8:01 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See IKT's money flow as a full page
Social Sentiment
No Reddit posts found for IKT.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.